Not All FoxP3-Positive Lymphocytes Are Equal: Spatial Localization Predicts Survival in Pancreatic Cancer
Published in Cancer, General & Internal Medicine, and Immunology
Why Study FoxP3?
FoxP3-positive lymphocytes are commonly associated with regulatory T-cell activity and immune suppression. Although several studies have examined FoxP3 in pancreatic cancer, most evaluated it as a single measurement without considering where these immune cells were located.
We hypothesized that the biological significance of FoxP3-positive lymphocytes might depend on their spatial distribution within the tumor microenvironment.
To investigate this question, we analyzed 98 surgically resected PDAC cases and separately assessed FoxP3 expression in three distinct compartments:
- Intratumoral (IT)
- Peritumoral (PT)
- Tumor-associated stromal (T)
This compartment-based approach enabled a more detailed characterization of the immune landscape surrounding pancreatic cancer.
High FoxP3 Expression Predicts Poorer Overall Survival
One of the most striking findings of our study was the consistent association between elevated FoxP3 expression and reduced overall survival.
Across all evaluated compartments, patients with high FoxP3 expression demonstrated significantly shorter overall survival than those with low expression.
These findings suggest that immunosuppressive immune populations contribute to aggressive tumor behavior regardless of their precise anatomical location.
High FoxP3 Expression Also Predicts Earlier Recurrence
Overall survival represents only one aspect of clinical outcome. We therefore evaluated disease-free survival to determine whether FoxP3-positive lymphocytes were also associated with tumor recurrence.
Figure 8. Kaplan–Meier disease-free survival curves according to FoxP3 expression.
Patients exhibiting higher FoxP3 expression experienced earlier recurrence following surgical resection. This finding suggests that FoxP3-associated immune suppression may influence not only mortality but also mechanisms driving disease progression and relapse.
Prognostic Effects Persist in Patients Receiving Adjuvant Therapy
An important question was whether FoxP3 retained prognostic significance among patients receiving postoperative chemotherapy.
Interestingly, compartment-specific FoxP3 expression remained associated with survival outcomes even within this clinically important subgroup. These findings support the robustness of spatial immune profiling and suggest that FoxP3-related biology may remain relevant despite systemic treatment.
Why Spatial Pathology Matters
Traditional pathology has always relied on spatial information. Pathologists routinely evaluate tumor invasion, lymphovascular invasion, surgical margins, and many other features based on anatomical relationships.
Our findings suggest that immune biomarkers should be approached similarly.
Rather than simply determining whether immune cells are present, future pathology workflows may increasingly focus on where these cells are located and how they interact with surrounding structures.
Advances in digital pathology, artificial intelligence, multiplex imaging, and spatial transcriptomics may further enhance our ability to characterize these complex relationships.
Key Findings
🔬 98 resected PDAC patients were evaluated.
📍 FoxP3-positive lymphocytes were assessed separately in intratumoral, peritumoral, and stromal compartments.
📈 High FoxP3 expression predicted significantly shorter overall survival.
📉 High FoxP3 expression predicted shorter disease-free survival.
🧬 Spatial localization provided clinically meaningful prognostic information.
🚀 Spatial pathology approaches may improve future biomarker development and personalized treatment strategies.
Citation
Kandemir H, Solakoglu Kahraman D, Aktas S, Unal OU, Cagiral S. Spatially Resolved FoxP3 Positive Lymphocyte Infiltration Within the Tumor Microenvironment Predicts Survival in Resected Pancreatic Ductal Adenocarcinoma. Discover Oncology. 2026. DOI: 10.1007/s12672-026-05195-7
Follow the Topic
-
Discover Oncology
This is a fully open access general oncology journal that aims to provide a unified forum for researchers and clinicians. The journal spans from basic and translational science, to preclinical, clinical, and epidemiology, and welcomes content that interfaces at all levels of cancer research.
Related Collections
With Collections, you can get published faster and increase your visibility.
Advances in Gastrointestinal and Neuroendocrine Malignancies
Gastrointestinal (GI) cancers and neuroendocrine neoplasms (NENs) represent a diverse and clinically challenging group of malignancies with rising global incidence especially among younger individuals. Colorectal, gastric, pancreatic, biliary tract, and hepatocellular carcinomas together account for a major proportion of cancer-related deaths worldwide. Similarly, NENs—once considered rare—are rising in incidence with heterogeneity in biology, clinical course, and response to therapy. Despite major progress in systemic treatments, surgical techniques, and molecular profiling, outcomes remain suboptimal for many patients.
In recent years, comprehensive molecular profiling has not only provided novel insights into tumor biology and resistance mechanisms but also helped uncover several actionable therapeutic targets. Parallel advances in immunotherapy, targeted therapies, and radiopharmaceuticals have reshaped the treatment landscape for select patient populations. At the same time, efforts to better understand tumor–microenvironment interactions, clonal evolution, and mechanisms of therapeutic resistance are yielding new opportunities for translational research.
This Collection aims to highlight recent advances in the biology, diagnosis, and management of GI cancers and NENs. We invite contributions spanning molecular and cellular mechanisms, biomarker discovery, innovative therapeutic strategies, clinical trial design, and translational approaches that bridge the gap from bench to bedside. Together, these works will underscore the evolving paradigms that hold promise for improving outcomes in these complex diseases.
Keywords: Gastrointestinal cancers, neuroendocrine neoplasms, biomarkers, tumor microenvironment, immunotherapy, radiopharmaceuticals, precision oncology, translational research
Publishing Model: Open Access
Deadline: Nov 06, 2026
The Evolving Landscape of Lung Cancer: Advances in Diagnosis, Treatment Strategies, and Simultaneous Care
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, although recent years have seen remarkable progress in its clinical management. This Collection aims to deepen the evolving landscape of lung cancer through a comprehensive lens, including early diagnosis, molecular profiling (through liquid and tissue), therapeutic innovation, and simultaneous care strategies. The Collection will gather original research, reviews, short reports or letters and case studies focused on:
advances in early detection and biomarker discovery and development;
the evolution of precision oncology and molecular profiling;
updates on systemic therapies, including immunotherapy and targeted agents;
novel treatment combination strategies,
the increasing integration of simultaneous care into multidisciplinary models for improving patient outcomes.
Keywords: lung cancer; precision oncology; immunotherapy; molecular diagnostics; simultaneous care
Publishing Model: Open Access
Deadline: Dec 04, 2026
